Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CONMED Corporation’s (NYSE: CNMD) U.S. Securities and Exchange Commission filings, with AI-powered tools to help interpret the information. CONMED files a variety of reports under the Securities Exchange Act of 1934, and its common stock is registered on the New York Stock Exchange under the symbol CNMD, as noted in multiple Form 8-K filings.
For this medical equipment company in the surgical and medical instrument manufacturing industry, SEC filings are a primary source for understanding its financial condition, operating performance and strategic actions. Current reports on Form 8-K disclose events such as quarterly and year-to-date financial results, portfolio optimization steps, changes in directors and executive officers, dividend declarations, and share repurchase authorizations. For example, recent 8-K filings describe the announcement of second and third quarter financial results, the intent to exit gastroenterology product lines, the appointment of a new independent director, the resignation of a director, the declaration of a quarterly cash dividend, and a planned transition of the Chief Financial Officer.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when accessed through this page, contain detailed financial statements, segment information for orthopedic and general surgery, and discussions of items that are later referenced in non-GAAP reconciliations, such as product rationalization costs, operational optimization consulting fees, executive transition costs, legal matters, contingent consideration fair value adjustments, restructuring and related costs, and other specified items. These filings also provide context for guidance on revenue and adjusted diluted earnings per share that CONMED discusses in its press releases and investor presentations.
In addition to giving direct access to the underlying documents, this page uses AI to summarize key points from lengthy filings, highlight important sections, and surface items related to topics such as portfolio changes, capital allocation decisions, and leadership transitions. Users can review CONMED’s historical and current SEC disclosures here, along with AI-generated insights that explain the significance of each filing in clear language.
CONMED Corporation reported higher profitability for the quarter ended March 31, 2026, despite slightly lower sales. Net sales were $317.0 million versus $321.3 million a year earlier, mainly because gastroenterology product revenue fell to $9.5 million from $25.0 million as the company exited that portfolio.
Net income more than doubled to $13.8 million from $6.0 million, and diluted EPS rose to $0.45 from $0.19, helped by stronger gross margins and lower selling and administrative costs. Gross margin expanded to 57.9% from 55.3%, aided by a benefit from terminating the Gore VIABIL biliary stent distribution agreement and lower supply-chain consulting costs. Operating cash flow declined to $13.5 million from $41.5 million, reflecting working-capital swings and higher incentive payments. The company generated $7.0 million from selling certain gastroenterology assets, repurchased $37.0 million of stock, and ended the quarter with $35.0 million in cash and $860.9 million of total debt, including $800.0 million of 2.250% convertible notes due 2027 that it plans to refinance.
CONMED Corp reports beneficial ownership of 1,619,070 shares as of 03/31/2026. Vanguard Capital Management states it has sole dispositive power over 1,619,070 shares and sole voting power over 235,028 shares, representing 5.25% of the class. The filing names affiliated Vanguard entities that exercise dispositive or voting power on certain managed accounts.
CONMED Corporation reported first quarter 2026 net sales of $317.0 million, down 1.3% year-over-year, as the exit of certain gastroenterology products reduced sales by $15.5 million. Domestic revenue fell 5.8%, while international revenue grew 4.7% as reported.
GAAP diluted earnings per share rose to $0.45 from $0.19 a year earlier, and adjusted diluted EPS was $0.89 versus $0.95. EBITDA was $44.3 million and adjusted EBITDA was $56.4 million, compared to $61.3 million in 2025.
Management raised its 2026 outlook for organic constant currency revenue growth to 5.0%–6.5% and now expects full-year reported revenue of $1.350 billion to $1.375 billion, while reaffirming adjusted diluted EPS guidance of $4.30 to $4.45.
CONMED Corp reported that Vanguard Portfolio Management beneficially owns 2,120,886 shares of Common Stock, representing 6.87% of the class as reported in a Schedule 13G. The filing states Vanguard has sole dispositive power over 2,120,886 shares and sole voting power over 44,469 shares. The filing is signed by Ashley Grim and dated 04/29/2026.
CONMED Corporation is asking stockholders to vote at its 2026 virtual annual meeting on three items: electing seven directors, approving an advisory say‑on‑pay vote and ratifying PricewaterhouseCoopers as auditor for 2026.
Management highlights 2025 revenue of $1.375 billion, up 5.2%, with orthopedics sales up 5.5% and general surgery up 4.7% in constant currency, driven by platforms such as AirSeal and Buffalo Filter. The Board suspended the quarterly dividend effective October 31, 2025 and expanded authorization for a $150 million share repurchase program while exiting gastroenterology product lines to focus on minimally invasive surgery, smoke evacuation and orthopedic soft tissue repair.
The proxy details leadership changes, including the January 2025 promotion of Pat Beyer to President and CEO and ongoing CFO succession, as well as significant Board refreshment, an independent Chair structure, director term limits and enhanced stock ownership and clawback policies. Executive and director pay programs emphasize performance‑based incentives, relative total shareholder return, and strong alignment with stockholders.
Beyer Pat reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp President & CEO Pat Beyer received a grant of 28,145 RSUs, representing a $1 million target-value equity award. The RSUs are scheduled to vest over three years in three equal annual tranches starting April 1, 2026, with a two-year post-vest holding period on net after-tax shares. Following this grant, Beyer directly holds 28,145 RSUs tied to CONMED common stock, designed to align compensation with longer-term company performance.
The Vanguard Group filed an amendment (Schedule 13G/A) reporting zero beneficial ownership of CONMED Corp common stock. The filing states 03/13/2026 and is signed on 03/26/2026. It explains an internal realignment on January 12, 2026 that caused separate reporting by Vanguard subsidiaries and business divisions. The filing lists 0% ownership and 0 shares, and states no single external person holds more than 5% of the class.
Lalomia Brent reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation reported that Executive VP RA, QA Brent Lalomia received a corrected grant of 17,198 restricted stock units (RSUs) under the company’s 2025 Long-Term Incentive Plan. Each RSU represents one share of common stock, vesting 33% after one year, 33% after two years, and 34% after three years.
The filing explains that this amended Form 4 updates the originally reported 9,554 RSUs to include a special award of 7,644 additional RSUs, bringing the total grant to 17,198 units.
Schabacker Matthew reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation reported an amended Form 4 showing that executive Matthew Schabacker, VP GM Advanced Surgical, received a corrected grant of 17,471 restricted stock units (RSUs) under the company’s 2025 Long-Term Incentive Plan.
Each RSU represents a contingent right to one share of CONMED common stock. The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% in the second year, and 34% in the third year. The amendment clarifies that this total includes a special award of 7,644 RSUs in addition to the originally reported 9,827 RSUs.